Assessment of efficacy of Anti-IgE (Omalizumab) therapy in patients with severe allergic asthma in a tertiary care hospital of Eastern India

Simple item page
dc.contributor.authorGhosh, Sen_US
dc.contributor.authorGayen, Pen_US
dc.contributor.authorMandal, Aen_US
dc.contributor.authorBandyopadhyay, Ren_US
dc.date.accessioned2020-09-24T07:54:00Z
dc.date.available2020-09-24T07:54:00Z
dc.date.issued2019-06
dc.description.abstractIntroduction: Immunoglobulin E dependent mechanisms play an important role in the development of airway inflammation in allergic asthma. Atopic patients with severe asthma frequently have poorly controlled disease. Many have poor asthma control despite intensive treatment. Severe allergic asthma patients frequently treated with oral corticosteroids and therefore may develop serious side-effects. Anti-IgE antibody had been used in severe persistent allergic asthma in Western countries. However, its long-term efficacy in patients in India has not been reported. Objective: To assess the efficacy of anti IgE therapy in patients with severe allergic asthma. Method: 30 (16 male and 14 female) patients, with mean age of 49 having severe persistent allergic asthma, with recurrent exacerbations and on oral/IV steroids, received Omalizumab 150mg/300mg/450 mg for 1 year. Total dose of oral Steroids, use of rescue medications, changes in lung function (FEV1) were recorded at the baseline, 16 weeks & at end of the treatment (52 weeks) and then analyzed. Results: Significant reduction observed in total oral steroid use at 16 week & at 52 weeks. -10.5mg (p<0.003) & 22.5mg respectively. Use of rescue medications decreased by -7.90 puffs(p- <0.001) at 16 weeks and by -13.67 puffs (13.67 (p -<0.001) at 52 weeks. Improvements in lung Function (FEV1) observed with a tune of 700 ml. from Baseline after 52 weeks therapy. Conclusion: Use of anti-IgE antibody for 1 year is well tolerated and led to an overall significant improvement in patients with severe persistent allergic asthma.en_US
dc.identifier.affiliationsDr. Saswata Ghosh Assistant Professor, Chest Medicine, Malda Medical College and Hospital, West Bengal, Indiaen_US
dc.identifier.affiliationsDr. Prosenjit Gayen Assistant Professor, Pathology, Malda Medical College and Hospital, West Bengal, Indiaen_US
dc.identifier.affiliationsDr. Animesh Mandal Assistant Professor, Chest Medicine, Malda Medical College and Hospital, West Bengal, Indiaen_US
dc.identifier.affiliationsDr. Ramtanu Bandyopadhyay Professor, General Medicine, Malda Medical College and Hospital, West Bengal, Indiaen_US
dc.identifier.citationGhosh S, Gayen P, Mandal A, Bandyopadhyay R. Assessment of efficacy of Anti-IgE (Omalizumab) therapy in patients with severe allergic asthma in a tertiary care hospital of Eastern India. International Journal of Medical Research & Review. 2019 Jun; 7(3): 206-211en_US
dc.identifier.issn2320-8686
dc.identifier.issn2321-127X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/205266
dc.languageenen_US
dc.publisherSiddharth Health Research and Social Welfare Societyen_US
dc.relation.issuenumber3en_US
dc.relation.volume7en_US
dc.source.urihttps://ijmrr.medresearch.in/index.php/ijmrr/article/view/1060en_US
dc.subjectSevere allergic asthmaen_US
dc.subjectAnti IgE therapyen_US
dc.subjectOmalizumaben_US
dc.titleAssessment of efficacy of Anti-IgE (Omalizumab) therapy in patients with severe allergic asthma in a tertiary care hospital of Eastern Indiaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmrr2019v7n3p206.pdf
Size:
126.29 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Medical Research & Review